Kate Zhang

Kate Zhang has worked in the biotechnology industry for over 25 years. Kate began their career in 1996 as an Associate Director and Scientist to Senior Scientist at Science Strategy at Genzyme. In 2008, they were promoted to Director at Cell and Therapeutic Protein Development at Genzyme. In 2011, they moved to Global Bio-Therapeutic at Sanofi, where they served as Senior Director. In 2014, they were promoted to Senior Director at Global Translational Science at Sanofi. In 2018, they joined Editas Medicine as Vice President of Biological Development. Most recently, they were appointed Chief Scientific Officer at Hopewell Therapeutics Inc. in 2022.

Kate Zhang has an extensive educational history. From 1989 to 1994, they attended Queen's University, where they obtained a Ph.D in Analytical Chemistry. Prior to that, they earned a Master of Science from the Graduate School of the Chinese Academy of Science. Kate also holds a Bachelor of Engineering from TsingHua University. In addition, they completed a Post-Doc at the National Heart, Lung and Blood Institute, NIH, where they studied Laboratory of Biophysical Chemistry, Cell Biology, and Biological Mass Spectrometry.